NCT06184867Completed
Choices About Genetic Testing And Learning Your Risk With Smart Technology
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
This study seeks to enhance genetic education and increase the uptake of genetic testing for hereditary cancer risk among cancer survivors. The study will focus on the feasibility and acceptability of a digital intervention designed to improve cancer genomic care. The study objectives are to: 1. Finalize the development and optimize the usability of the CATALYST digital intervention (also known as the relational assistant \[RA\]). 2. Evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery model for cancer survivors. Participants will be randomized to one of two study arms: the RA intervention arm or the enhanced usual care (EUC) arm. 3. Assess the uptake of genetic counseling (GC) and genetic testing (GT) and conduct a process evaluation to identify barriers and facilitators to GC, GT, and engagement with the CATALYST intervention and the RA.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 7 Nov 2023
- Start date
- 26 Sept 2023
- Primary completion date
- 26 Jun 2025
- Lead sponsor
- Rutgers, The State University of New Jersey
- NCT number
- NCT06184867
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 26 Sept 2023 to the primary completion date, 26 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants will be 18 years of age or older because germline genetic testing is generally not recommended in children when the test results would not impact clinical management. Participants from the user and usability testing phases are not eligible for the feasibility trial. Feasibility trial participants cannot have previously undergone germline GT for hereditary cancer risk.
Who the study is looking for
- User/Usability Testing
- Age 18 or older
- Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer
- Speak/read and understand English
- Capable of providing informed consent
- Have Internet access (via smartphone, tablet, or computer)
- Randomized Feasibility Trial
- Age 18 or older
- Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer
- Meet National Comprehensive Cancer Network (NCCN) criteria for germline GT
- Speak/read and understand English
- Capable of providing informed consent
- Have Internet access (via smartphone, tablet or computer)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rutgers University Coordinator of this site? Confirm its status | New Brunswick | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.